Working with the ELF scientists was a real pleasure. They performed their work with a high level of quality and professionalism. More importantly, the scientists (now at BioAscent) who were involved in the hit development stage, were fully committed to the success of the project, bringing their own ideas and solutions, which made my role as project owner very comfortable. I would be very happy to work with them again.
- Dr Aubry Miller, Cancer Drug Discovery/Wirkstoffforschung Group Leader, German Cancer Research Center (DKFZ).
ODD has been working with BioAscent for over two years, since we transferred our entire compound management to them. The logistical services are reasonably priced and reduce the burden on our chemists for weighing and dispatching allowing greater productivity. BioAscent can accommodate varying storage requirements for our compounds that reflect differing stabilities and are able to perform analysis on the samples when needed. The shipping turnaround from BioAscent is always rapid and they can accommodate differing shipping formats and often, last-minute changes in our requirements.
- Oxford Drug Design
Our target and mechanism was challenging (an allosteric, covalent inhibitor approach). The proposal from the BioAscent team to support our project was detailed and well-thought-out, with references to show a good level of diligence. Likewise, on our early calls, it was clear that the team were experienced in screening covalent inhibitors. The project itself really benefited from BioAscent’s biology and chemistry expertise, and the collaborative and open approach that they have – they were happy to listen to our ideas, while at the same time not afraid to challenge and contribute – I really appreciated this attitude.
- Project Manager, Apollo Therapeutics
A key objective of the University of Edinburgh Cancer Drug Discovery group is to advance cell-based screening technologies beyond the current state-of-the-art. Our partnership with BioAscent combines our longstanding expertise in high content cell-based phenotypic screening with BioAscent's expertise in compound management and quality control processes for compound storage, identification and resupply. Our discussions with BioAscent have been very dynamic and interactive which has helped ensure we developed the compound management solution which best meets our needs. The ongoing relationship with BioAscent and their fast response times are directly supporting our broader goals to establish a world-leading cell-based screening capability which spans across multiple disease areas.
- Neil Carragher, Professor of Drug Discovery at the University of Edinburgh
VAST Bioscience was looking for a compound management provider that is competitively priced, and is fast and flexible in order to service both our screening collaborations of VAST libraries, and our internal drug discovery programs. We have been very pleased with the professionalism that BioAscent has brought to the table, in particular the rapid response and turnaround time for delivering plating orders and shipment, combined with the flexibility and attention to detail. BioAscent has been reliable, timely and accurate, and it was very pleasing to see the positive impact on our internal and external projects.
- VAST Bioscience